When cheeks appear flatter or the facial contour seems less defined, a wish for a subtle change is understandable. Profhilo® Structura is a hyaluronic-acid treatment associated with the volume of the lateral cheek. Online descriptions often speak of “regenerating fat tissue”. That wording needs careful scrutiny: a visible change after an injection does not establish which biological process produced it.
This guide separates the product concept, clinical observations and unanswered questions. It may help you decide whether to seek a consultation, but it cannot replace an examination or individual informed consent. Facial changes have different causes: skin quality, fat compartments, underlying bone structure and facial movement interact. A product name therefore cannot determine the right treatment by itself. The relevant questions are which feature is troubling you, what change you hope for and how much uncertainty you are willing to accept.
What is Profhilo® Structura?
Profhilo® Structura contains hybrid complexes of high- and low-molecular-weight hyaluronic acid. The manufacturer calls the production process NAHYCO® technology. Unlike a conventional strongly cross-linked volumising filler, the concept is not simply mechanical filling; the formulation has been studied for use in facial fat compartments. This does not automatically mean that existing fat tissue is permanently renewed. Composition and intended use explain the approach, not a guaranteed benefit for an individual patient.
“Lipolifting” is also a product or marketing term rather than a diagnosis. Before treatment, it should be clear whether the concern is truly the lateral cheek contour, a wrinkle, skin laxity or another change. These distinctions matter because findings from one studied area cannot simply be transferred to the whole face. Nor can a proposed mechanism establish that an outcome will look more natural than every alternative.
What does the clinical study actually show?
Sparavigna and colleagues studied Profhilo® Structura in an open-label pilot study involving 50 women with volume loss in the lateral cheek area. Participants received two treatments under the study protocol. Clinician-rated scales for volume loss and wrinkles improved from baseline; final follow-up took place three months after the second treatment. Those details describe the study, not a treatment schedule at PRECIOUS. The original paper can be found under PubMed PMID 38260185.
The study had no untreated group or group receiving another treatment. It therefore cannot reliably separate the product's contribution from the injection itself, variation in assessment or other influences. It was also small and brief. The researchers did not directly measure newly formed fat tissue; the discussion expressly identifies the lack of instrumental assessment as a limitation. An improvement on a volume-rating scale is not the same as proof of fat-tissue regeneration.
Does laboratory research prove regeneration in the face?
Another paper examined properties of the hyaluronic-acid complex and responses of human adipose-derived stromal cells in a laboratory setting. Experiments of this kind can support a biological hypothesis. They do not show whether lasting new fat cells form in a living face after treatment, how much the contour changes as a result or how long a visible effect lasts. A cell model is not a clinical comparison between treatment and no treatment. The laboratory paper is recorded under PubMed PMID 38396698.
This distinction is practical for patients: it is reasonable to find an observed aesthetic improvement interesting without treating it as proven tissue growth. The word “regenerates” may otherwise promise more than the available evidence supports. A claim that one method is generally gentler, longer-lasting or more natural than conventional fillers would also require direct comparisons. The pilot study does not provide such a comparison.
How does the decision differ from choosing a conventional filler?
A conventional hyaluronic-acid filler is often chosen to change a particular contour or volume deficit directly. Profhilo® Structura is presented with a different distribution pattern and a proposed tissue effect. These are different concepts, but not evidence that one is superior for every face. Marked volume loss, predominantly fine lines and lax skin may require different goals. An examination should separate these components before a product is recommended.
A skin booster or a treatment directed at the skin surface does not automatically pursue the same goal as a volume treatment. Different procedures could in theory be combined, but combining them is not an obligation and should not follow from product names alone. A sound consultation may equally conclude that no injection is appropriate for now. Someone with a specific contour goal should describe it clearly; someone seeking a general sense of freshness needs especially clear discussion of what can actually be measured.
Who might benefit from a consultation?
A consultation may be useful if a change in cheek contour bothers you and you want to know whether an injectable treatment fits your goal at all. Suitability cannot be judged from a photograph or a product term. Medical assessment needs to consider anatomy, earlier aesthetic procedures, existing conditions, medicines, allergies and your willingness to accept possible adverse effects. The pilot study excluded people with certain illnesses and during pregnancy or breastfeeding; this is not a complete list of individual contraindications.
Expectations matter just as much. A change in a study group's rating scale guarantees neither a “lifted” face nor a particular duration of effect for you. If you expect a pronounced contour correction, the consultation should openly address whether the studied product is suitable for that aim. If you do not want an injection, that is a valid decision in itself. Wanting a natural appearance does not justify calling any particular product risk-free.
Which risks should be discussed?
The Structura pilot study documented mild bruising and reported no serious adverse events in its small group during the observed period. That is not a safety guarantee. Pain, swelling, inflammatory reactions or an unwanted contour are also reasonable topics for individual informed consent. The pilot study cannot reliably calculate the probability of an event for a particular person. Before any injection, it should also be clear whom to contact if unexpected symptoms occur.
Facial filler injections can rarely affect blood vessels. A large retrospective cohort study of several fillers documented vascular occlusion with both needles and cannulas. Those data are not specific to Profhilo® Structura and must not be read as a product-specific risk rate; they do show why choosing an instrument cannot promise complete safety. Sudden severe pain, unusual skin discolouration or visual symptoms after a facial injection require immediate medical assessment. The study is available under PubMed PMID 33377939.
Which questions help before deciding?
- Which specific change is the treatment meant to address, and which facial features should remain unchanged?
- Which findings support this product rather than another approach or no treatment?
- What effect is realistic, which evidence is missing and when would the outcome be assessed?
- Which risks, costs and contact options for complications need clarification in advance?
Bring details of previous fillers, other procedures, medicines and known health conditions to the consultation. Ask whether a change is expected immediately or over time, and how it could be assessed without a before-and-after promise. Clear informed consent distinguishes research protocols from what a practice actually offers. It explains what may be planned for you without turning a small study into a fixed number of sessions or a predicted chance of success.
How should the PRECIOUS service be understood?
PRECIOUS is a private practice for internal medicine, longevity and aesthetic medicine in Wiesbaden. Its website lists Profhilo among its aesthetic services. That does not establish a specific Structura procedure, a particular technique or a fixed price. Such details belong in an individual medical consultation. The practice bills privately under the German medical fee schedule, GOÄ; understandable cost information should be available before you decide.
A good decision does not have to end in treatment. It may show that another approach addresses the concern better, or that uncertainty outweighs the expected benefit. The most useful consultation question is therefore not “Which product will make me younger?” but a precise description of the change you notice and the result you hope for. This keeps your priorities, medical suitability and the available evidence distinct from one another.
Sources
Sparavigna A et al. Efficacy and tolerability of Profhilo® Structura intended to restore lateral cheek fat compartment: An observational pilot study. Health Science Reports. 2024;7:e1743. PubMed PMID 38260185. Note the open-label design and manufacturer support.
Vassallo V et al. Highly Concentrated Stabilized Hybrid Complexes of Hyaluronic Acid: Rheological and Biological Assessment of Compatibility with Adipose Tissue and Derived Stromal Cells towards Regenerative Medicine. International Journal of Molecular Sciences. 2024;25:2019. PubMed PMID 38396698. Laboratory research, not clinical proof of efficacy.
Alam M et al. Rates of Vascular Occlusion Associated With Using Needles vs Cannulas for Filler Injection. JAMA Dermatology. 2021;157:174–180. PubMed PMID 33377939. The studied fillers must not be equated with Profhilo® Structura.
